6533b858fe1ef96bd12b62a8

RESEARCH PRODUCT

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Anja MeurerEdwin DejesusEdwin DejesusMaria Jesus Pérez-eliasNorbert H. BrockmeyerKaram MounzerFrançois RomanLaurence WeissStefan SchneiderMarguerite KoutsoukosJean-daniel LelièvreOdile LaunayJihad SlimOlivier BouchaudFranco FelizartaIan FrankNathalie Colin De VerdièreFrançois RaffiFelipe GarcíaThomas HarrerSusan SwindellsDaniel PodzamczerJohn D. BaxterStefan EsserWarren DingesPierre Marie GirardAlix CollardChristine KatlamaEnrique Ortega GonzalezBonaventura Clotet SalaGilles PialouxJulie ChasSusan L. KoletarGuy Patrick YeniPatricia BourguignonJean-michel MolinaRafael Rubio

subject

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article

description

Supplemental Digital Content is available in the text

https://hdl.handle.net/20.500.12530/27529